Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Daily News

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

Yael L. Maxwell

December 11, 2019

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

News Opinion Editor's Corner

ISCHEMIA Questions? Some Answers From David Maron

Shelley Wood

December 09, 2019

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Daily News

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

Michael O'Riordan

November 29, 2019

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

News Daily News

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Todd Neale

November 07, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Daily News

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

Todd Neale

September 19, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Advertisement

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

ISCHEMIA Questions? Some Answers From David Maron

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

TCTMD’s Top 10 Most Popular Stories for September 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content